FAM114A2

Across TCGA pan-cancer cohorts, FAM114A2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM114A2 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher FAM114A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM114A2 expression acts as an unfavorable survival marker.

ACC, MESO, and LIHC are the cancer types where FAM114A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.214	0.802	.002	15	view →
MESO	DFS	Median	II,III,IV	0.039	0.407	<.001	12	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FAM114A2–ACC (OS)

Open the ACC breakdown →